Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Manitoba

$17,500.00

Investigating the mechanism of L-Rham-induced cell killing in high-grade serous ovarian cancer.

FY 2023-24

Summary
Ovarian cancer is the fifth leading cause of cancer death in Canadian women. The most common and deadly type of ovarian cancer is high-grade serous ovarian cancer (HGSOC). HGSOC is treated by removing the cancer with surgery in combination with chemotherapy (drugs used to treat cancer cells). However, after treatment, the majority of patients develop the cancer again and eventually become resistant to chemotherapy. This means that the cancer no longer responds to the chemotherapy drugs currently available. Therefore, it is important to find new drugs to treat HGSOC in order to help patients survive the disease. We have shown that glycosylated antitumour ether lipids (GAELs) are a new class of experimental drugs that can kill chemotherapy-resistant HGSOC cells. This is likely due to the fact that GAELs kill cancer cells in a different way than the current chemotherapy drugs. However, we still don’t know the exact mechanism as to how GAELs kill cancer cells. This project aims to determine how one kind of GAEL, L-Rham, kills HGSOC cells. L-Rham could potentially be a model for how all GAELs kill HGSOC cells. My initial research has shown that L-Rham causes the energy producing units in our cells, the mitochondria, to become short-circuited, meaning they are unable to function. My project will explore this further by measuring changes in molecules related to mitochondrial function. I will also look at molecules related to different cell death pathways to see how they might be affected. Ultimately, this research may lead to GAELs as a new treatment option to help all HGSOC patients fight their cancer.
Program
Master's Award: Canada Graduate Scholarships
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
505977
Name
Crooks Sara K
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the mechanism of L-Rham-induced cell killing in high-grade serous ovarian cancer.
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Epithelial Ovarian Cancer; Glycosylated Antitumour Ether Lipids; High-Grade Serous Ovarian Cancer; Mitochondria; Mitophagy; Novel Therapeutic; Ovarian Cancer; Oxidative Phosphorylation; Reactive Oxygen Species; Rna Sequencing
Abstract
Ovarian cancer is the fifth leading cause of cancer death in Canadian women. The most common and deadly type of ovarian cancer is high-grade serous ovarian cancer (HGSOC). HGSOC is treated by removing the cancer with surgery in combination with chemotherapy (drugs used to treat cancer cells). However, after treatment, the majority of patients develop the cancer again and eventually become resistant to chemotherapy. This means that the cancer no longer responds to the chemotherapy drugs currently available. Therefore, it is important to find new drugs to treat HGSOC in order to help patients survive the disease. We have shown that glycosylated antitumour ether lipids (GAELs) are a new class of experimental drugs that can kill chemotherapy-resistant HGSOC cells. This is likely due to the fact that GAELs kill cancer cells in a different way than the current chemotherapy drugs. However, we still don’t know the exact mechanism as to how GAELs kill cancer cells. This project aims to determine how one kind of GAEL, L-Rham, kills HGSOC cells. L-Rham could potentially be a model for how all GAELs kill HGSOC cells. My initial research has shown that L-Rham causes the energy producing units in our cells, the mitochondria, to become short-circuited, meaning they are unable to function. My project will explore this further by measuring changes in molecules related to mitochondrial function. I will also look at molecules related to different cell death pathways to see how they might be affected. Ultimately, this research may lead to GAELs as a new treatment option to help all HGSOC patients fight their cancer.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Crooks, Sara K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~